Replies to post #140270 on Biotech Values

[jq1234]

I didn't listen to the call. From press release, ECYT fund and finish ph3 OC trial which is a relatively large trial, MRK basically take over everything else. NSCLC ph2 is a much smaller trial. It would be interesting to see what MRK do.